Recombinant alpha interferon in retreatment of two patients with pulmonary lymphoma. Dramatic responses with resolution of pulmonary complications.
Two patients with advanced lymphoma involving the lungs that was resistant to chemotherapy had an initial excellent response to interferon therapy. After two months of stable disease, alpha interferon A therapy was discontinued, with relapse of a few months later. Both patients had extensive pulmonary involvement with relapse of the lymphoma, and both showed a dramatic response to retreatment with alpha interferon A. Unusual interferon-related pulmonary complications were observed in one patient, and their management is detailed.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D008207:Lymphatic Metastasis; D008223:Lymphoma / Q000000981:diagnostic imaging / Q000628:therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D011859:Radiography; D012128:Respiratory Distress Syndrome / Q000209:etiology
D000305:Adrenal Cortex Hormones; D004274:DNA, Recombinant; D007370:Interferon Type I